Patents Assigned to Aventis Pharma Deutschland GmbH
  • Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders
    Publication number: 20050019795
    Abstract: The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis.
    Type: Application
    Filed: April 23, 2004
    Publication date: January 27, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Detlef Kozian, Joerg Czech, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace
  • Nover diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use
    Publication number: 20050020563
    Abstract: The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.
    Type: Application
    Filed: March 31, 2004
    Publication date: January 27, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Wendelin Frick, Andreas Lindenschmidt, Stefanie Flohr, Hubert Heuer, Hans-Ludwig Schaefer, Werner Kramer, Eric Galia, Heiner Glombik
  • Modified antisense nucleotides complementary to a section of the human haras gene
    Publication number: 20050020523
    Abstract: The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy.
    Type: Application
    Filed: December 11, 2003
    Publication date: January 27, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Anuschirwan Peyman, David Will, Esther Chang, Kathleen Pirollo, Antonina Rait
  • Perfusion process for producing erythropoietin
    Publication number: 20050019914
    Abstract: The invention relates to a process for producing erythropoietin (EPO) in which eukaryotic cells, which are suitable for expressing EPO, are adapted to SMIF7 medium in a suitable bioreactor, the resulting cells are transferred to a larger bioreactor and further expanded with SMIF7 medium and, while constantly bleeding and constantly perfusing, the expressed EPO is isolated from the larger bioreactor and purified.
    Type: Application
    Filed: July 22, 2004
    Publication date: January 27, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Staerk, Klaus Scharfenberg, Norbert Schulze, Kathrin Baumeister, Wilhelm Beltz
  • Derivatives of 3-(guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
    Publication number: 20050014758
    Abstract: The present invention discloses and claims compounds of formula I and their pharmaceutically acceptable salts, and methods of using said compounds of formula I, either alone or in combination with other medicaments, as antiarrhythmic medicaments with a cardioprotective component for prophylaxis or treatment of infarction, for the treatment of angina pectoris, and as inhibitors of pathophysiological processes associated with the development of ischemia-induced damage, in particular in the triggering of ischemia-induced cardiac arrhythmias and of heart failure. Pharmaceutical compositions comprising compounds of formula I or compounds of formula I in combination with one or more other medicaments and processes for the preparation of compounds of formula I are also disclosed and claimed.
    Type: Application
    Filed: June 10, 2004
    Publication date: January 20, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Jean-Christophe Carry, Gilles Doerflinger, Arielle Genevois-Borella, Michel Evers, Alain Le Brun, Jean-Paul Martin, Pascal Desmazeau, Serge Mignani, Heinz-Werner Kleemann
  • Use of calpain for identifying compounds that modulate pain
    Publication number: 20050014182
    Abstract: The invention relates to the use of calpain or functional fragments or derivatives thereof for the preparation of pharmaceutical compounds that modulate pain, and the use of calpain or functional fragments of derivatives thereof for identifying such compounds, and a method of screening pharmaceuticals useful for modulating and/or preventing pain.
    Type: Application
    Filed: July 7, 2004
    Publication date: January 20, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Martin Michaelis, Gerd Geisslinger, Ellen Niederberger
  • Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
    Publication number: 20050014704
    Abstract: Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof. The invention relates to substituted aromatic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and process for their preparation. The compounds are suitable for example as antidiabetics.
    Type: Application
    Filed: December 12, 2003
    Publication date: January 20, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Wendelin Frick, Heiner Glombik, Werner Kramer, Hurbert Heuer, Harm Brummerhop, Oliver Plettenburg
  • Carbonylamino-substituted acyl phenyl urea derivatives, process for their preparation and their use
    Publication number: 20050014822
    Abstract: The invention relates to compounds of the formula I in which the radicals are defined as specified, and also to their physiologically tolerated salts. The compounds are suitable, for example, as medicaments for preventing and treating type 2 diabetes.
    Type: Application
    Filed: January 23, 2004
    Publication date: January 20, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Elisabeth Defossa, Dieter Kadereit, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt, Erich Von Roedern, Karl Schoenafinger, Alfons Enhsen
  • Substituted 4-amino-2aryl-pyrimidines, their production and use and pharmaceutical preparations containing same
    Patent number: 6844347
    Abstract: The invention relates to compounds of formula I, in which R1, R2, R3 and R4 have the meanings given in the claims. Said compounds are valuable active ingredients for the treatment and prophylaxis of diseases, for example of cardiovascular diseases such as hypertension, angina pectoris, heart failure, thrombosis or atherosclerosis. The compounds of the formula I are able to modulate the body's production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the treatment and prophylaxis of disorders associated with impaired cGMP balance. The invention furthermore relates to methods for producing compounds of the formula I, their use in the treatment and prophylaxis of the above diseases and in the preparation of medicaments for such diseases, and pharmaceutical preparations containing the compounds of formula I.
    Type: Grant
    Filed: August 4, 1999
    Date of Patent: January 18, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Ursula Schnidler, Karl Schoenafinger, Hartmut Strobel
  • Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
    Patent number: 6844361
    Abstract: This invention is directed to a pharmaceutical composition comprising the sodium-hydrogen exchanger (NHE) inhibitor cariporide and an angiotensin converting enzyme (ACE) inhibitor which exhibits unexpectedly efficacious properties for preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life, and to methods of preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life comprising administering pharmaceutically effective amounts of the sodium-hydrogen exchange inhibitor cariporide and an ACE inhibitor.
    Type: Grant
    Filed: February 4, 2003
    Date of Patent: January 18, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Wolfgang Linz, Ursula Schindler
  • Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
    Publication number: 20050009863
    Abstract: Substituted 4-phenyltetrahydroisoquinolines of formula I, process for their preparation, their use as a medicament and medicaments containing them. The compounds of formula I can be used, among other uses, in the event of renal disorders such as acute or chronic renal failure, in the event of disorders of biliary function, in the event of respiratory disorders such as snoring or sleep apneas or in the event of stroke.
    Type: Application
    Filed: March 24, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Armin Hofmeister, Uwe Heinelt, Hans-Jochen Lang, Wendelin Frick, Markus Bleich, Klaus Wirth
  • Triazole-derivatives as factor Xa inhibitors
    Publication number: 20050009827
    Abstract: The present invention is directed to the compound of formula I which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 13, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Marc Nazare, Volker Laux, Armin Bauer, Michael Wagner
  • Pharmaceutical composition comprising a sodium hydrogen exchange inhibitor and an angiotensin converting enzyme inhibitor
    Publication number: 20050009899
    Abstract: This invention is directed to a pharmaceutical composition comprising the sodium-hydrogen exchanger (NHE) inhibitor cariporide and an angiotensin converting enzyme (ACE) inhibitor which exhibits unexpectedly efficacious properties for preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life, and to methods of preventing heart failure and other age-related organ dysfunctions, age-related disorders and for prolonging life comprising administering pharmaceutically effective amounts of the sodium-hydrogen exchange inhibitor cariporide and an ACE inhibitor.
    Type: Application
    Filed: August 4, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Wolfgang Linz, Ursula Schindler
  • Polyamide nucleic acid derivatives, and agents, and processes for preparing them
    Publication number: 20050009073
    Abstract: The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents.
    Type: Application
    Filed: June 2, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Eugen Uhlmann, Gerhard Breipohl, David Will
  • Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
    Publication number: 20050010051
    Abstract: The present invention provides various processes for the preparation of (R)-?-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
    Type: Application
    Filed: May 6, 2004
    Publication date: January 13, 2005
    Applicants: Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
    Inventors: Jonathan Evans, Sandra Stolz-Dunn, Ian Tomlinson
  • Benzimidazole-derivatives as factor Xa inhibitors
    Publication number: 20050009829
    Abstract: The present invention relates to compounds of the formula I, wherein R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
    Type: Application
    Filed: May 19, 2004
    Publication date: January 13, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Marc Nazare, Michael Wagner, Volkmar Wehner, Hans Matter, Matthias Urmann, Kurt Ritter
  • Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them
    Publication number: 20050009864
    Abstract: The invention relates to compounds of the formula I in which R1 to R9 are as defined herein. In one embodiment, these compounds may be used as antihypertensives, for reducing or preventing ischemia-induced damage, as medicaments for surgical intervention for the treatment of ischemias of the nervous system, of stroke and of cerebral edema, of shock, of impaired respiratory drive, for the treatment of snoring, as laxative, as agent against ectoparasites, to prevent the formation of gallstones, as antiatherosclerotics, agents against late complications of diabetes, cancers, fibrotic disorders, endothelial dysfunction, organ hypertrophies and hyperplasias. In one embodiment, the compounds may be inhibitors of the cellular sodium-proton antiporter and influence serum lipoproteins and thus be used for the prophylaxis and for the regression of atherosclerotic lesions.
    Type: Application
    Filed: June 14, 2004
    Publication date: January 13, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Armin Hofmeister, Uwe Heinelt, Hans-Jochen Lang, Markus Bleich, Klaus Wirth, Michael Gekle
  • Pyrazoloisoquinoline derivatives for inhibiting NF?B-inducing kinase
    Patent number: 6841556
    Abstract: Compounds of the formula I are suitable for producing pharmaceuticals for the prophylaxis and therapy of diseases whose course involves an increased activity of NIK.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: January 11, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Stefanie Flohr, Thorsten Naumann
  • Imino acid derivatives as inhibitors of matrix metalloproteinases
    Publication number: 20050004166
    Abstract: The invention relates to a bicycloazaheterocyclyl carboxylic acid sulfonamide derivative of formula I herein, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use.
    Type: Application
    Filed: January 5, 2004
    Publication date: January 6, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Manfred Schudok, Sven Ruf, Hans Matter, Volkmar Wehner, Reinhard Kirsch, Petra Stahl
  • Selective MMP-13 inhibitors
    Publication number: 20050004111
    Abstract: The invention relates to a pyrimidine-4,6-dicarboxylic acid diamide compound, pharmaceutical preparation comprising it, process for preparing it and method for its pharmaceutical use. Particularly, the pyrimidine-4,6-dicarboxylic acid diamide compound is useful for selectively inhibiting collagenase matrix metalloproteinase (MMP) 13, or for treating a degenerative joint disease.
    Type: Application
    Filed: January 5, 2004
    Publication date: January 6, 2005
    Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH
    Inventors: Otmar Klingler, Reinhard Kirsch, Joerg Habermann, Klaus-Ulrich Weithmann, Christian Engel, Bernard Pirard